COVID-19 and Gynecologic Oncology: What Have We Learned?

Opinion statement COVID-19 has transformed the care we provide to gynecologic oncology patients. In addition to directly impacting the diagnosis and treatment of women with gynecologic cancer, it has affected our patient’s ability to undergo recommended surveillance and has made an impact on every c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Current treatment options in oncology 2021-12, Vol.22 (12), p.117-117, Article 117
Hauptverfasser: Leibold, Aurora, Papatla, Katyayani, Zeligs, Kristen P., Blank, Stephanie V.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 117
container_issue 12
container_start_page 117
container_title Current treatment options in oncology
container_volume 22
creator Leibold, Aurora
Papatla, Katyayani
Zeligs, Kristen P.
Blank, Stephanie V.
description Opinion statement COVID-19 has transformed the care we provide to gynecologic oncology patients. In addition to directly impacting the diagnosis and treatment of women with gynecologic cancer, it has affected our patient’s ability to undergo recommended surveillance and has made an impact on every caregiver providing care during this time. Herein we review the current literature on the impact of COVID-19 on gynecologic oncology and highlight new approaches and innovations that have resulted in gynecologic cancer care as a result of the pandemic. The impact of COVID-19 on the field of gynecologic oncology has been profound. In addition to directly impacting the diagnosis and treatment of women with cancer, it has also challenged the very ethics with which we practice medicine. The equitable distribution of resources is paramount to upholding the Hippocratic Oath which we all invoke. The COVID-19 pandemic has stripped this oath down to its very core, forcing all medical practitioners to scrutinize who gets what resources and when. As the pandemic continues to unfold, the question remains — in the setting of a strained and overburdened healthcare system, how do we maximize beneficence to one group of patients, while maintaining non-maleficence to others? As gynecologic oncologists, we are responsible for advocating for our patients to ensure that the quality of their cancer care is not compromised, while also not overutilizing resources that are sorely needed for the care of COVID-19 victims, and not making them more likely to succumb to COVID-19 by the very nature of the treatment we provide. The effects of the pandemic are far-reaching and broad, and many of these are yet to be determined. Future studies are needed to analyze how the above-utilized strategies in GYN cancer care during the pandemic will impact the long-term outcomes of our patients.
doi_str_mv 10.1007/s11864-021-00905-5
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8609172</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2601566063</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-dceae7755fbd6173f08920cc614fe31c6cda7d40ffe3247bd2ba38f8396fde503</originalsourceid><addsrcrecordid>eNp9kctKAzEUhoMo1tsLuJABN26iJ_cZF4pUrUKhGy_LkGYy7cg0o0lb6Nubtt4XrnLC-c6XHH6EDgmcEgB1FgnJJcdACQYoQGCxgXaIYBxLqtTmsqYKU0WLDtqN8QWACg7FNuownhNaKLaD8u7g6f4akyIzvsx6C-9s27Sj2mYDv6oW59nz2EyzOzN32bPL-s4E78rLfbRVmSa6g49zDz3e3jx073B_0LvvXvWx5YpPcWmdcUoJUQ1LSRSrIC8oWCsJrxwjVtrSqJJDlW6Uq2FJh4blVc4KWZVOANtDF2vv62w4cUnnp8E0-jXUExMWujW1_t3x9ViP2rnOJRRE0SQ4-RCE9m3m4lRP6mhd0xjv2lnUVALhuaCwRI__oC_tLPi03ooSUoJkiaJryoY2xuCqr88Q0Mtg9DoYnYLRq2C0SENHP9f4GvlMIgFsDcTU8iMXvt_-R_sOf1aXOA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2601566063</pqid></control><display><type>article</type><title>COVID-19 and Gynecologic Oncology: What Have We Learned?</title><source>MEDLINE</source><source>Springer Online Journals</source><creator>Leibold, Aurora ; Papatla, Katyayani ; Zeligs, Kristen P. ; Blank, Stephanie V.</creator><creatorcontrib>Leibold, Aurora ; Papatla, Katyayani ; Zeligs, Kristen P. ; Blank, Stephanie V.</creatorcontrib><description>Opinion statement COVID-19 has transformed the care we provide to gynecologic oncology patients. In addition to directly impacting the diagnosis and treatment of women with gynecologic cancer, it has affected our patient’s ability to undergo recommended surveillance and has made an impact on every caregiver providing care during this time. Herein we review the current literature on the impact of COVID-19 on gynecologic oncology and highlight new approaches and innovations that have resulted in gynecologic cancer care as a result of the pandemic. The impact of COVID-19 on the field of gynecologic oncology has been profound. In addition to directly impacting the diagnosis and treatment of women with cancer, it has also challenged the very ethics with which we practice medicine. The equitable distribution of resources is paramount to upholding the Hippocratic Oath which we all invoke. The COVID-19 pandemic has stripped this oath down to its very core, forcing all medical practitioners to scrutinize who gets what resources and when. As the pandemic continues to unfold, the question remains — in the setting of a strained and overburdened healthcare system, how do we maximize beneficence to one group of patients, while maintaining non-maleficence to others? As gynecologic oncologists, we are responsible for advocating for our patients to ensure that the quality of their cancer care is not compromised, while also not overutilizing resources that are sorely needed for the care of COVID-19 victims, and not making them more likely to succumb to COVID-19 by the very nature of the treatment we provide. The effects of the pandemic are far-reaching and broad, and many of these are yet to be determined. Future studies are needed to analyze how the above-utilized strategies in GYN cancer care during the pandemic will impact the long-term outcomes of our patients.</description><identifier>ISSN: 1527-2729</identifier><identifier>EISSN: 1534-6277</identifier><identifier>EISSN: 1534-5277</identifier><identifier>DOI: 10.1007/s11864-021-00905-5</identifier><identifier>PMID: 34812973</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Cancer ; Coronaviruses ; COVID-19 ; COVID-19 - diagnosis ; COVID-19 - prevention &amp; control ; COVID-19 - transmission ; Delivery of Health Care - standards ; Diagnosis ; Female ; Genital Neoplasms, Female - therapy ; Genital Neoplasms, Female - virology ; Gynecologic Cancers (LA Cantrell ; Gynecologic Cancers (LA Cantrell, Section Editor) ; Humans ; Infection Control - methods ; Medical diagnosis ; Medicine ; Medicine &amp; Public Health ; Oncologists - standards ; Oncology ; Pandemics ; Patients ; Practice Patterns, Physicians' - standards ; SARS-CoV-2 - isolation &amp; purification ; Section Editor ; Topical Collection on Gynecologic Cancers</subject><ispartof>Current treatment options in oncology, 2021-12, Vol.22 (12), p.117-117, Article 117</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-dceae7755fbd6173f08920cc614fe31c6cda7d40ffe3247bd2ba38f8396fde503</citedby><cites>FETCH-LOGICAL-c474t-dceae7755fbd6173f08920cc614fe31c6cda7d40ffe3247bd2ba38f8396fde503</cites><orcidid>0000-0002-5333-9484 ; 0000-0001-9160-3939 ; 0000-0003-3372-0402 ; 0000-0003-4191-5154</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11864-021-00905-5$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11864-021-00905-5$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34812973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leibold, Aurora</creatorcontrib><creatorcontrib>Papatla, Katyayani</creatorcontrib><creatorcontrib>Zeligs, Kristen P.</creatorcontrib><creatorcontrib>Blank, Stephanie V.</creatorcontrib><title>COVID-19 and Gynecologic Oncology: What Have We Learned?</title><title>Current treatment options in oncology</title><addtitle>Curr. Treat. Options in Oncol</addtitle><addtitle>Curr Treat Options Oncol</addtitle><description>Opinion statement COVID-19 has transformed the care we provide to gynecologic oncology patients. In addition to directly impacting the diagnosis and treatment of women with gynecologic cancer, it has affected our patient’s ability to undergo recommended surveillance and has made an impact on every caregiver providing care during this time. Herein we review the current literature on the impact of COVID-19 on gynecologic oncology and highlight new approaches and innovations that have resulted in gynecologic cancer care as a result of the pandemic. The impact of COVID-19 on the field of gynecologic oncology has been profound. In addition to directly impacting the diagnosis and treatment of women with cancer, it has also challenged the very ethics with which we practice medicine. The equitable distribution of resources is paramount to upholding the Hippocratic Oath which we all invoke. The COVID-19 pandemic has stripped this oath down to its very core, forcing all medical practitioners to scrutinize who gets what resources and when. As the pandemic continues to unfold, the question remains — in the setting of a strained and overburdened healthcare system, how do we maximize beneficence to one group of patients, while maintaining non-maleficence to others? As gynecologic oncologists, we are responsible for advocating for our patients to ensure that the quality of their cancer care is not compromised, while also not overutilizing resources that are sorely needed for the care of COVID-19 victims, and not making them more likely to succumb to COVID-19 by the very nature of the treatment we provide. The effects of the pandemic are far-reaching and broad, and many of these are yet to be determined. Future studies are needed to analyze how the above-utilized strategies in GYN cancer care during the pandemic will impact the long-term outcomes of our patients.</description><subject>Cancer</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - diagnosis</subject><subject>COVID-19 - prevention &amp; control</subject><subject>COVID-19 - transmission</subject><subject>Delivery of Health Care - standards</subject><subject>Diagnosis</subject><subject>Female</subject><subject>Genital Neoplasms, Female - therapy</subject><subject>Genital Neoplasms, Female - virology</subject><subject>Gynecologic Cancers (LA Cantrell</subject><subject>Gynecologic Cancers (LA Cantrell, Section Editor)</subject><subject>Humans</subject><subject>Infection Control - methods</subject><subject>Medical diagnosis</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Oncologists - standards</subject><subject>Oncology</subject><subject>Pandemics</subject><subject>Patients</subject><subject>Practice Patterns, Physicians' - standards</subject><subject>SARS-CoV-2 - isolation &amp; purification</subject><subject>Section Editor</subject><subject>Topical Collection on Gynecologic Cancers</subject><issn>1527-2729</issn><issn>1534-6277</issn><issn>1534-5277</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kctKAzEUhoMo1tsLuJABN26iJ_cZF4pUrUKhGy_LkGYy7cg0o0lb6Nubtt4XrnLC-c6XHH6EDgmcEgB1FgnJJcdACQYoQGCxgXaIYBxLqtTmsqYKU0WLDtqN8QWACg7FNuownhNaKLaD8u7g6f4akyIzvsx6C-9s27Sj2mYDv6oW59nz2EyzOzN32bPL-s4E78rLfbRVmSa6g49zDz3e3jx073B_0LvvXvWx5YpPcWmdcUoJUQ1LSRSrIC8oWCsJrxwjVtrSqJJDlW6Uq2FJh4blVc4KWZVOANtDF2vv62w4cUnnp8E0-jXUExMWujW1_t3x9ViP2rnOJRRE0SQ4-RCE9m3m4lRP6mhd0xjv2lnUVALhuaCwRI__oC_tLPi03ooSUoJkiaJryoY2xuCqr88Q0Mtg9DoYnYLRq2C0SENHP9f4GvlMIgFsDcTU8iMXvt_-R_sOf1aXOA</recordid><startdate>20211201</startdate><enddate>20211201</enddate><creator>Leibold, Aurora</creator><creator>Papatla, Katyayani</creator><creator>Zeligs, Kristen P.</creator><creator>Blank, Stephanie V.</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-5333-9484</orcidid><orcidid>https://orcid.org/0000-0001-9160-3939</orcidid><orcidid>https://orcid.org/0000-0003-3372-0402</orcidid><orcidid>https://orcid.org/0000-0003-4191-5154</orcidid></search><sort><creationdate>20211201</creationdate><title>COVID-19 and Gynecologic Oncology: What Have We Learned?</title><author>Leibold, Aurora ; Papatla, Katyayani ; Zeligs, Kristen P. ; Blank, Stephanie V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-dceae7755fbd6173f08920cc614fe31c6cda7d40ffe3247bd2ba38f8396fde503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cancer</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - diagnosis</topic><topic>COVID-19 - prevention &amp; control</topic><topic>COVID-19 - transmission</topic><topic>Delivery of Health Care - standards</topic><topic>Diagnosis</topic><topic>Female</topic><topic>Genital Neoplasms, Female - therapy</topic><topic>Genital Neoplasms, Female - virology</topic><topic>Gynecologic Cancers (LA Cantrell</topic><topic>Gynecologic Cancers (LA Cantrell, Section Editor)</topic><topic>Humans</topic><topic>Infection Control - methods</topic><topic>Medical diagnosis</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Oncologists - standards</topic><topic>Oncology</topic><topic>Pandemics</topic><topic>Patients</topic><topic>Practice Patterns, Physicians' - standards</topic><topic>SARS-CoV-2 - isolation &amp; purification</topic><topic>Section Editor</topic><topic>Topical Collection on Gynecologic Cancers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leibold, Aurora</creatorcontrib><creatorcontrib>Papatla, Katyayani</creatorcontrib><creatorcontrib>Zeligs, Kristen P.</creatorcontrib><creatorcontrib>Blank, Stephanie V.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Current treatment options in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Leibold, Aurora</au><au>Papatla, Katyayani</au><au>Zeligs, Kristen P.</au><au>Blank, Stephanie V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COVID-19 and Gynecologic Oncology: What Have We Learned?</atitle><jtitle>Current treatment options in oncology</jtitle><stitle>Curr. Treat. Options in Oncol</stitle><addtitle>Curr Treat Options Oncol</addtitle><date>2021-12-01</date><risdate>2021</risdate><volume>22</volume><issue>12</issue><spage>117</spage><epage>117</epage><pages>117-117</pages><artnum>117</artnum><issn>1527-2729</issn><eissn>1534-6277</eissn><eissn>1534-5277</eissn><abstract>Opinion statement COVID-19 has transformed the care we provide to gynecologic oncology patients. In addition to directly impacting the diagnosis and treatment of women with gynecologic cancer, it has affected our patient’s ability to undergo recommended surveillance and has made an impact on every caregiver providing care during this time. Herein we review the current literature on the impact of COVID-19 on gynecologic oncology and highlight new approaches and innovations that have resulted in gynecologic cancer care as a result of the pandemic. The impact of COVID-19 on the field of gynecologic oncology has been profound. In addition to directly impacting the diagnosis and treatment of women with cancer, it has also challenged the very ethics with which we practice medicine. The equitable distribution of resources is paramount to upholding the Hippocratic Oath which we all invoke. The COVID-19 pandemic has stripped this oath down to its very core, forcing all medical practitioners to scrutinize who gets what resources and when. As the pandemic continues to unfold, the question remains — in the setting of a strained and overburdened healthcare system, how do we maximize beneficence to one group of patients, while maintaining non-maleficence to others? As gynecologic oncologists, we are responsible for advocating for our patients to ensure that the quality of their cancer care is not compromised, while also not overutilizing resources that are sorely needed for the care of COVID-19 victims, and not making them more likely to succumb to COVID-19 by the very nature of the treatment we provide. The effects of the pandemic are far-reaching and broad, and many of these are yet to be determined. Future studies are needed to analyze how the above-utilized strategies in GYN cancer care during the pandemic will impact the long-term outcomes of our patients.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>34812973</pmid><doi>10.1007/s11864-021-00905-5</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-5333-9484</orcidid><orcidid>https://orcid.org/0000-0001-9160-3939</orcidid><orcidid>https://orcid.org/0000-0003-3372-0402</orcidid><orcidid>https://orcid.org/0000-0003-4191-5154</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1527-2729
ispartof Current treatment options in oncology, 2021-12, Vol.22 (12), p.117-117, Article 117
issn 1527-2729
1534-6277
1534-5277
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8609172
source MEDLINE; Springer Online Journals
subjects Cancer
Coronaviruses
COVID-19
COVID-19 - diagnosis
COVID-19 - prevention & control
COVID-19 - transmission
Delivery of Health Care - standards
Diagnosis
Female
Genital Neoplasms, Female - therapy
Genital Neoplasms, Female - virology
Gynecologic Cancers (LA Cantrell
Gynecologic Cancers (LA Cantrell, Section Editor)
Humans
Infection Control - methods
Medical diagnosis
Medicine
Medicine & Public Health
Oncologists - standards
Oncology
Pandemics
Patients
Practice Patterns, Physicians' - standards
SARS-CoV-2 - isolation & purification
Section Editor
Topical Collection on Gynecologic Cancers
title COVID-19 and Gynecologic Oncology: What Have We Learned?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T07%3A15%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COVID-19%20and%20Gynecologic%20Oncology:%20What%20Have%20We%20Learned?&rft.jtitle=Current%20treatment%20options%20in%20oncology&rft.au=Leibold,%20Aurora&rft.date=2021-12-01&rft.volume=22&rft.issue=12&rft.spage=117&rft.epage=117&rft.pages=117-117&rft.artnum=117&rft.issn=1527-2729&rft.eissn=1534-6277&rft_id=info:doi/10.1007/s11864-021-00905-5&rft_dat=%3Cproquest_pubme%3E2601566063%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2601566063&rft_id=info:pmid/34812973&rfr_iscdi=true